Prof. Scott T. Tagawa, Weill Cornell Medicine, United States
Prof. Tagawa shares key insights from ASCO GU 2026, highlighting how the combination of enzalutamide and radium-223 in the PEACE-3 study may reshape the first-line treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). He also discusses the broader implications for precision treatment strategies and the evolving future of prostate cancer care.
Watch the full interview for comprehensive expert perspectives.